Nyrada Inc (NYR)
20mins delayed
Movement
1 Year Return
Nyrada Inc Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $16.74 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
NYR Statistics
15 July
1,549 / 2,232
ASX Size Rank
1yr Return
vs Sector (1yr)
-28.43%
vs ASX 200 (1yr)
+2.47%
$16.74 million
Market Cap
Share Issue
76.07 million
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
15 July
N/A
PE Ratio
EPS ($)
-
Earnings Yield
-
NTA ($)
-
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Nyrada Inc (NYR) is a preclinical stage, drug development company. The Company specialises in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. It focuses on areas of substantial unmet clinical need and has identified drug candidates with therapeutic and commercial potential, where few if any, effective or well-tolerated therapies exist. It currently has three wholly-owned drug programs:
Upcoming Calendar
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
NYR is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr Peter Ashley Marks | Non-Executive Director | Aug 2017 |
|
| Dr Graham E Kelly | Founder, Non-Executive Director | Aug 2017 |
|
| Mr John Alexander Moore | Non-Executive Chairman, Non-Executive Director | Jun 2019 |
|
| Mr Ruediger Weseloh | Non-Executive Director | Jun 2019 |
|
| Mr Christopher Cox | Non-Executive Director | Nov 2019 |
|
| Mr Marcus Frampton | Non-Executive Director | Jun 2019 |
|
| Mr David Franks | Company Secretary | - | |
| Mr James Bonnar | Chief Executive Officer | - |
Director Transactions
NYR directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 23/04/20 | John Moore | Buy | +35,000 | $0.168 | $5,882 | On-market trade. |
Shareholder Distribution
Shareholder Distribution data is unavailable.
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| Noxopharm Limited | 33,373,245 | 30.51% |
| Altnia Holding Pty Ltd | 9,921,725 | 9.07% |
| Goodridge Nominees Pty Ltd | 6,212,416 | 5.68% |
| Goodridge Nominees Pty Ltd |
6,212,416 | 5.68% |
| Colin Housely & Freda Housely |
1,863,725 | 1.70% |
| Sunset Capital Management Pty Ltd |
1,500,000 | 1.37% |
| John W King Nominees Pty Ltd | 1,242,483 | 1.14% |
| Kohen Enterprises Pty Ltd | 1,070,000 | 0.98% |
| Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon |
925,000 | 0.85% |
| RHLC Pty Limited |
838,675 | 0.77% |
| Symphony Capital Holdings Llc | 800,000 | 0.73% |
| Citicorp Nominees Pty Limited | 750,000 | 0.69% |
| CS Third Nominees Pty Limited |
750,000 | 0.69% |
| Sunshine Group Investments Pty Ltd |
625,000 | 0.57% |
| Baywick Pty Ltd |
621,241 | 0.57% |
| Lawsam Pty Ltd | 621,241 | 0.57% |
| Phytose Corporation Pty Limited |
466,551 | 0.43% |
| Wolseley Road #1 Pty Limited |
375,000 | 0.34% |
| AKJ Super Pty Ltd |
375,000 | 0.34% |
| Albany Mechanical Services Pty Ltd |
375,000 | 0.34% |
| Xcel Capital Pty Ltd | 325,000 | 0.30% |
| Boris Patkin | 310,620 | 0.28% |
| Mirage Investments Pty Ltd | 300,000 | 0.27% |
| Mr Graham Arthur Robinson | 300,000 | 0.27% |
| Kalcon Investments Pty Ltd | 300,000 | 0.27% |
| DRP 2006 Super Pty Ltd |
292,425 | 0.27% |
| GT Capital Pty Ltd | 265,000 | 0.24% |
| All other shareholders | 35.08 % | |
The Top 20 Shareholders of NYR hold 64.92% of shares on issue.
NYR Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
NYR Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Drug research and development.
Incorporated: --
1209 Orange St
Wilmington Delaware USA 19801
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.